News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News ESC 2024 Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery Todd Neale August 30, 2024
News Conference News ESC 2022 DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark L.A. McKeown August 30, 2022
News Conference News ESC 2021 Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD Michael O'Riordan August 28, 2021
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Conference News ESC 2019 New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL Michael O'Riordan September 05, 2019
News Conference News ESC 2019 New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises Michael O'Riordan September 04, 2019
News Conference News ESC 2019 DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics Shelley Wood September 01, 2019
News Conference News ESC 2019 Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS Michael O'Riordan September 01, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News ESC 2015 Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes Yael L. Maxwell September 01, 2015
News Conference News ESC 2015 TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics Yael L. Maxwell August 31, 2015
News Conference News ESC 2015 Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients L.A. McKeown August 31, 2015
News Conference News ESC 2015 FREEDOM Substudy: CABG, PCI Outcomes Affected by Baseline BP Yael L. Maxwell August 30, 2015